Zobrazeno 1 - 10
of 31
pro vyhledávání: '"A. I. Zagrebneva"'
Autor:
A. M. Lila, I. Z. Gaydukova, O. N. Anoshenkova, I. G. Bannikova, I. B. Vinogradova, M. L. Goldman, S. Yu. Davidian, L. P. Evstigneeva, O. E. Epifanova, E. V. Zemerova, A. I. Zagrebneva, L. V. Ivanova, A. K. Karibova, I. V. Menshikova, O. N. Mironenko, M. P. Mikhailova, N. E. Nikulenkova, I. M. Patrikeeva, T. V. Plaksina, G. R. Savvina, R. R. Samigullina, L. E. Sarantseva, J. V. Usacheva, O. P. Ukhanova, G. F. Fatkhullina, A. L. Chudinov, I. A. Shafieva, S. P. Yakupova
Publikováno v:
Современная ревматология, Vol 18, Iss 3, Pp 32-43 (2024)
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of
Externí odkaz:
https://doaj.org/article/4031788a32de403ebea6e82d4f01065d
Autor:
E. L. Nasonov, V. N. Amirjanova, Y. A. Olyunin, Y. V. Muravyev, A. A. Baranov, E. V. Zonova, E. N. Otteva, A. I. Zagrebneva, D. I. Abdulganieva, P. I. Pchelnikova
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 4, Pp 435-449 (2023)
Rheumatoid arthritis (RA) is the most frequent immunoinflammatory (autoimmune) rheumatic disease characterized by chronic erosive arthritis and systemic damage to internal organs. The data obtained in the course of basic research on deciphering the m
Externí odkaz:
https://doaj.org/article/622d326a6fcc4ceba244273a93e899a0
Autor:
A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, E. O. Morozova, Zh. M. Kodzeva, K. S. Sapogina
Publikováno v:
Современная ревматология, Vol 16, Iss 6, Pp 73-79 (2022)
Objective: to confirm the efficacy and safety of levilimab in patients with rheumatoid arthritis (RA) switched from other interleukin 6 receptor inhibitors (iIL6R) for non-medical reasons.Patients and methods. A retrospective analysis of data from th
Externí odkaz:
https://doaj.org/article/3997aa7967654dbe93e600df9003064a
Autor:
E. L. Nasonov, A. M. Lila, V. I. Mazurov, B. S. Belov, A. E. Karateev, T. V. Dubinina, O. A. Nikitinskaya, A. A. Baranov, D. I. Abdulganieva, S. V. Moiseev, A. I. Zagrebneva
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 3, Pp 239-254 (2021)
In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is
Externí odkaz:
https://doaj.org/article/b7f263ddf821441cb26b075f990e2ab7
Autor:
L. P. Ananieva, S. N. Avdeev, I. Е. Tyurin, A. М. Lila, A. I. Zagrebneva, А. L. Maslyanskiy, S. A. Terpigorev, I. V. Stepanyan, E. L. Lashina, O. V. Vasilieva, O. S. Lukina, E S. Pershina, А. А. Klimenko, N. A. Shostak, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 6, Pp 631-636 (2021)
The problem of fibrosing interstitial lung diseases (ILDs) unites specialists from different areas: pulmonologists, radiologists, therapists, rheumatologists, occupational doctors and others. Actual achievements in studying fibrosing ILDs which are c
Externí odkaz:
https://doaj.org/article/e431526f7a0f4efbab5af6f04a2d5afe
Publikováno v:
Современная ревматология, Vol 13, Iss 3, Pp 82-86 (2019)
In 2008, the term cardiorenal syndrome (CRS) was proposed by the Acute Dialysis Quality Initiative (ADQI) Group to denote pathological reciprocal conditions involving the heart and kidneys, which develop due to acute or chronic dysfunction of one of
Externí odkaz:
https://doaj.org/article/dcec55bef71441f0821e20c127a6854f
Autor:
Alena I. Zagrebneva, Elena N. Simonova, Тatiana V. Mezenova, Natalia B. Burmistrova, Yuliya A. Gavrikova, Vladislav V. Dolgov, Evgeniya O. Morozova, Zhaneta M. Kodzeva, Ksenia S. Sapogina, Anastasia A. Fomina
Publikováno v:
HERALD of North-Western State Medical University named after I.I. Mechnikov. 14:83-92
The growing demand for biological disease-modifying antirheumatic drugs (bDMARDs) and their high cost put a heavy burden on the healthcare budget, thereby limiting the availability of treatment for patients. The introduction of bDMARDs biosimilars in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e7df88fab6a1b47c2ae2d7e856841e
https://doi.org/10.17816/mechnikov116731
https://doi.org/10.17816/mechnikov116731
Publikováno v:
Problems of Social Hygiene, Public Health and History of Medicine. 30:1004-1009
The article is a comparative analysis of the quality of life indicators of patients with rheumatoid arthritis with similar indicators in the Moscow population. We conducted a survey of patients in the register of rheumatoid patients in Moscow using t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9cab7a7f4ac1d5f89438577cd0fcd3
https://doi.org/10.32687/0869-866x-2022-30-s1-1004-1009
https://doi.org/10.32687/0869-866x-2022-30-s1-1004-1009
Autor:
Ulyana A. Mаrkina, Daria S. Fomina, Marina S. Lebedkina, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva, Zinaida Yu. Mutovina, Alexander V. Karaulov, Ekaterina I. Alexeeva, Mariana A. Lysenko
Publikováno v:
Terapevticheskii arkhiv. 94:675-682
The use of virus-neutralizing monoclonal antibodies is an effective method of etiotropic therapy for SARS-CoV-2 in patients of high-risk groups of severe COVID-19. Regdanvimab is a single-component monoclonal antibodies immunoglobulin G1, whose mecha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58bfd7871246250281299e0180909ce7
https://doi.org/10.26442/00403660.2022.05.201690
https://doi.org/10.26442/00403660.2022.05.201690
Autor:
Vladimir P. Chulanov, Bulat A. Bakirov, Natalia N. Vezikova, Vladimir N. Gorodin, Marina V. Zhuravleva, Alena I. Zagrebneva, Igor G. Ivanov, Nikita V. Lomakin, Galina V. Lukina, Diana L. Moysova, Zinaida I. Mutovina
Publikováno v:
Terapevticheskii arkhiv. 94(8)
The Advisory Board chaired by the chief specialist in infectious diseases of the Ministry of Health of Russian Federation, Professor V.P. Chulanov was held on June 18, 2022 in Saint Petersburg. Aim. The main purpose of the Board was following discuss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a70b0869dc3e9c2a37b80d8673682017
https://pubmed.ncbi.nlm.nih.gov/36286985
https://pubmed.ncbi.nlm.nih.gov/36286985